• Humacyte (NASDAQ:HUMA) is up ~6% in Friday trading after reporting that a U.S. FDA review of its acellular tissues engineered vessel (ATEV) for vascular trauma is ongoing.
• The news provides a sigh of relief after the company said in August that the agency would need additional time to review the application. The original action date was Aug. 10.
• BTIG analyst Ryan Zimmerman, who rates Humacyte a buy, wrote that the development is a positive sign and "suggests that there is forward progress." And while he expects ATEV will win approval, he added the "timing is difficult to handicap."

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。